Neuromyelitis Optica Spectrum Disorder Market Size, Share & Trends Analysis and Forecast 2021-2030

The neuromyelitis optica spectrum disorder (NMOSD) market in China was valued at $116.1 million in 2020. Over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of more than 20%. Major driver for the growth of the market will be the introduction of novel pipeline agents. In order of entry, these products will be Uplizna (inebilizumab), telitacicept, and Ultomiris (ravulizumab). Therefore, the gradual shift towards the use of biologics and mAbs is forecasted to further drive the market growth, because of the emerging clinical evidence of their efficacy in reducing NMOSD attacks coupled with the recent drug pricing reforms that aim to increase reimbursement of innovative drugs.

The greatest unmet need in the NMOSD market is the high cost of innovative drugs including mAbs, in addition to their treatment-related costs. However, this situation is expected to be addressed in the future due to the recent reforms to the country’s National Reimbursement Drug List (NRDL) and revised price cuts with foreign pharma companies. Furthermore, the need for efficacious preventative therapies is expected to be addressed with the launch of a few effective disease-modifying biologics during the forecast period. NMOSD market will exhibit significant growth between 2020 and 2030, driven by the launches of late-stage pipeline agents and the anticipated increased reimbursement of biologics.

Overview of the neuromyelitis optica spectrum disorder market

For more insights on this report, download a free report sample

What are the drugs being used for the neuromyelitis optica spectrum disorder (NMOSD)?

In 2020, the top-selling marketed drug was found to be Soliris, primarily due to its extremely high cost. However, it is anticipated to show a marked decline after 2026, when the patent for Soliris expires and the introduction of its biosimilars such as Samsung Bioepis SB12 (AMT904) start gaining market share. Between 2020 and 2030, all the marketed corticosteroids and off-label immunosuppressants except for mAbs and biosimilars will see an overall decline in sales, due to the shift towards using biologics that are more effective in relapsing NMOSD.

The projected entry of three late-stage pipeline agents into the market over the forecast period is expected to coincide with the increased use of novel mAbs and biosimilars. This presents an opportunity for increased reimbursement and pricing negotiations to further expand the target patient pool. The pipeline drug that will gain the largest market share will be Uplizna in 2030.

Neuromyelitis optica spectrum disorder (NMOSD) by drug and classes, 2020

For more channel insights, download a free report sample

What are the diagnosed prevalent cases of neuromyelitis optica spectrum disorder in China?

The diagnosed prevalent cases of NMOSD in China was 50,598 in 2020 and is forecasted to reach 51,320 cases by 2030, at an annual growth rate of 0.14%. The two clinically and commercially relevant phenotypes considered in this forecast are NMOSD (AQP4+) and NMOSD (AQP4-). In 2020, in China, there were 42,098 cases of AQP4+ and 8,500 cases of AQP4- diagnosed prevalent cases of NMOSD among men and women of all ages.

What is the neuromyelitis optica spectrum disorder (NMOSD) pipeline overview in China?

The NMOSD pipeline in China is varied, with several novel therapeutic classes. Their mechanisms of action (MOAs) range from immunosuppressive strategies and B cell depletion to mAbs seeking label expansion.

Clinical development for NMOSD has steadily grown in recent years; there are currently three pipeline drugs in late-stage development. All these drugs are expected to be launched throughout the forecast period.

There are seven pipeline products in active development for NMOSD in China in Phases I, II, and III. The majority of those are innovative IV-administered biologic drugs. Recent reforms have accelerated the approval process of biologics from material submission to final approval to nearly six months. Therefore, the focus of drug developers in the NMOSD pipeline has been agents that lower the risk of attacks and relapses in patients with AQP4 autoantibodies, which in turn reduces the risk of disabilities.

Market report scope

Scope

This report provides a comprehensive analysis of the neuromyelitis optica spectrum disorder market:

• Overview of NMOSD, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized NMOSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (anti-AQP4+ NMOSD and anti-AQP4- NMOSD) forecast from 2020 to 2030.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the NMOSD therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for NMOSD therapy. The most promising candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global NMOSD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecasts include one country

Forecasts cover three time points: base year, 5-year, and 10-year

The prevalence of NMOSD is increasing in line with population growth in China.

Major unmet needs are expected to be partially addressed by 2030, however, the opportunity to develop a curative drug remains.

The NMOSD pipeline is dominated by innovative biologics that are looking to suppress the risk of relapses and disabilities.

NMOSD market will exhibit significant growth between 2020 and 2030, driven by the launches of late-stage pipeline agents and the anticipated increased reimbursement

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global NMOSD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NMOSD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.